Corporate ActionJun 4, 2026, 05:14 PM
NRx Pharmaceuticals Closes $22.3M Public Offering
AI Summary
NRx Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of common stock at a public offering price of $3.50 per share. The offering generated approximately $22.3 million in gross proceeds before deducting underwriting discounts and other estimated expenses. The company intends to use the net proceeds for working capital and general corporate purposes to support its growth.
Key Highlights
- NRx Pharmaceuticals closed its underwritten public offering of common stock.
- The public offering price was $3.50 per share of common stock.
- Gross proceeds from the offering were approximately $22.3 million.
- Net proceeds will be used for working capital and general corporate purposes.
- BTIG, LLC served as the lead bookrunning manager for the offering.
Price Impact
More from NRXP